These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 31444839)

  • 1. Relationships Between Allopurinol Dose, Oxypurinol Concentration and Urate-Lowering Response-In Search of a Minimum Effective Oxypurinol Concentration.
    Stamp LK; Chapman PT; Barclay M; Horne A; Frampton C; Merriman TR; Wright DFB; Drake J; Dalbeth N
    Clin Transl Sci; 2020 Jan; 13(1):110-115. PubMed ID: 31444839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level.
    Stamp LK; Barclay ML; O'Donnell JL; Zhang M; Drake J; Frampton C; Chapman PT
    Clin Pharmacol Ther; 2011 Sep; 90(3):392-8. PubMed ID: 21796116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How much allopurinol does it take to get to target urate? Comparison of actual dose with creatinine clearance-based dose.
    Stamp LK; Chapman PT; Barclay ML; Horne A; Frampton C; Tan P; Drake J; Dalbeth N
    Arthritis Res Ther; 2018 Nov; 20(1):255. PubMed ID: 30446002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Individualising the dose of allopurinol in patients with gout.
    Kannangara DRW; Graham GG; Wright DFB; Stocker SL; Portek I; Pile KD; Barclay ML; Williams KM; Stamp LK; Day RO
    Br J Clin Pharmacol; 2017 Sep; 83(9):2015-2026. PubMed ID: 28417592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Furosemide increases plasma oxypurinol without lowering serum urate--a complex drug interaction: implications for clinical practice.
    Stamp LK; Barclay ML; O'Donnell JL; Zhang M; Drake J; Frampton C; Chapman PT
    Rheumatology (Oxford); 2012 Sep; 51(9):1670-6. PubMed ID: 22539486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of kidney function on the urate lowering effect and safety of increasing allopurinol above doses based on creatinine clearance: a post hoc analysis of a randomized controlled trial.
    Stamp LK; Chapman PT; Barclay M; Horne A; Frampton C; Tan P; Drake J; Dalbeth N
    Arthritis Res Ther; 2017 Dec; 19(1):283. PubMed ID: 29268756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An audit of a therapeutic drug monitoring service for allopurinol therapy.
    Kannangara DR; Ramasamy SN; Ray JE; Jones G; Graham GG; Williams KM; Day RO
    Ther Drug Monit; 2013 Dec; 35(6):863-6. PubMed ID: 24263644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ABCG2 loss-of-function polymorphism predicts poor response to allopurinol in patients with gout.
    Roberts RL; Wallace MC; Phipps-Green AJ; Topless R; Drake JM; Tan P; Dalbeth N; Merriman TR; Stamp LK
    Pharmacogenomics J; 2017 Mar; 17(2):201-203. PubMed ID: 26810134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The optimal use of allopurinol: an audit of allopurinol use in South Auckland.
    Stamp L; Gow P; Sharples K; Raill B
    Aust N Z J Med; 2000 Oct; 30(5):567-72. PubMed ID: 11108066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout.
    Stamp LK; Chapman PT; Barclay ML; Horne A; Frampton C; Tan P; Drake J; Dalbeth N
    Ann Rheum Dis; 2017 Sep; 76(9):1522-1528. PubMed ID: 28314755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting allopurinol response in patients with gout.
    Wright DF; Duffull SB; Merriman TR; Dalbeth N; Barclay ML; Stamp LK
    Br J Clin Pharmacol; 2016 Feb; 81(2):277-89. PubMed ID: 26451524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-Dose Allopurinol Promotes Greater Serum Urate Lowering in Gout Patients with Chronic Kidney Disease Compared with Normal Kidney Function.
    Toprover M; Crittenden DB; Modjinou DV; Oh C; Krasnokutsky S; Fisher MC; Keenan RT; Pillinger MH
    Bull Hosp Jt Dis (2013); 2019 Mar; 77(2):87-91. PubMed ID: 31140959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease.
    Panomvana D; Sripradit S; Angthararak S
    J Clin Rheumatol; 2008 Feb; 14(1):6-11. PubMed ID: 18431090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allopurinol dose escalation to achieve serum urate below 6 mg/dL: an open-label extension study.
    Stamp LK; Chapman PT; Barclay M; Horne A; Frampton C; Tan P; Drake J; Dalbeth N
    Ann Rheum Dis; 2017 Dec; 76(12):2065-2070. PubMed ID: 28830881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of peritoneal dialysis on oxypurinol and urate elimination in people with gout.
    Wilson LC; Ward J; Wright DFB; Green SC; Stocker SL; Putt TL; Schollum JBW; Walker RJ
    Nephrology (Carlton); 2024 Aug; 29(8):547-550. PubMed ID: 38626950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can we predict inadequate response to allopurinol dose escalation? Analysis of a randomised controlled trial.
    Stamp LK; Chapman PT; Barclay M; Horne A; Frampton C; Tan P; Drake J; Dalbeth N
    Rheumatology (Oxford); 2018 Dec; 57(12):2183-2189. PubMed ID: 30107437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Usefulness of combination treatment using allopurinol and benzbromarone for gout and hyperuricemia accompanying renal dysfunction: kinetic analysis of oxypurinol].
    Ohno I; Okabe H; Yamaguchi Y; Saikawa H; Uetake D; Hikita M; Gomi H; Ichida K; Hosoya T
    Nihon Jinzo Gakkai Shi; 2008; 50(4):506-12. PubMed ID: 18546882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The population pharmacokinetics of allopurinol and oxypurinol in patients with gout.
    Wright DF; Stamp LK; Merriman TR; Barclay ML; Duffull SB; Holford NH
    Eur J Clin Pharmacol; 2013 Jul; 69(7):1411-21. PubMed ID: 23475133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A population pharmacokinetic model to predict oxypurinol exposure in patients on haemodialysis.
    Wright DF; Doogue MP; Barclay ML; Chapman PT; Cross NB; Irvine JH; Stamp LK
    Eur J Clin Pharmacol; 2017 Jan; 73(1):71-78. PubMed ID: 27683090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics, pharmacodynamics and pharmacogenetics modelling of oxypurinol in Hmong adults with gout and/or hyperuricemia.
    Wen YF; Brundage RC; Roman YM; Culhane-Pera KA; Straka RJ
    Br J Clin Pharmacol; 2023 Oct; 89(10):2964-2976. PubMed ID: 37202871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.